ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NVAX Novavax Inc

4.06
0.11 (2.78%)
Last Updated: 09:18:56
Delayed by 15 minutes

Period:

Draw Mode:

Volume 443,050
Bid Price 4.06
Ask Price 4.07
News -
Day High 4.07

Low
3.5324

52 Week Range

High
11.36

Day Low 3.92
Share Name Share Symbol Market Stock Type
Novavax Inc NVAX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.11 2.78% 4.06 09:18:56
Open Price Low Price High Price Close Price Previous Close
3.97 3.92 4.07 3.95
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
1,995 443,050 US$ 4.01 US$ 1,776,229 - 3.5324 - 11.36
Last Trade Type Quantity Price Currency
09:18:57 1 US$ 4.07 USD

Novavax (NVAX) Options Flow Summary

Overall Flow

Bearish

Net Premium

-114k

Calls / Puts

0.00%

Buys / Sells

200.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Novavax Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
552.81M 139.95M - 983.71M -545.06M -3.89 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Novavax News

Date Time Source News Article
4/15/202405:00GlobeNewswire Inc.Shah Capital nominates two highly qualified independent..
4/01/202407:00PR Newswire (US)Novavax Presents Data on Updated COVID-19 Vaccine and..
3/05/202418:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/29/202415:02PR Newswire (US)Novavax to Participate in TD Cowen's 44th Annual Health Care..
2/28/202407:07Edgar (US Regulatory)Form 8-K - Current report
2/28/202407:00PR Newswire (US)Novavax Reports Fourth Quarter and Full Year 2023 Financial..
2/28/202406:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/23/202407:03IH Market NewsGoldman Sachs Reconsiders Fed Cuts, LUNR Surges Over 40% in..
2/22/202405:02Edgar (US Regulatory)Form 8-K - Current report
2/22/202405:00PR Newswire (US)Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine..
2/20/202408:25PR Newswire (US)Novavax to Host Conference Call to Discuss Fourth Quarter..
1/31/202407:00Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NVAX Message Board. Create One! See More Posts on NVAX Message Board See More Message Board Posts

Historical NVAX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.894.363.864.073,030,2620.174.37%
1 Month4.824.853.814.253,626,507-0.76-15.77%
3 Months4.016.053.53244.767,266,3560.051.25%
6 Months6.207.493.53245.057,297,408-2.14-34.52%
1 Year7.6611.363.53246.577,670,385-3.60-47.00%
3 Years209.49277.79993.532454.186,375,476-205.43-98.06%
5 Years10.136331.53883.532461.425,722,261-6.08-59.94%

Novavax Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Your Recent History

Delayed Upgrade Clock